Efficacy of EGFR TKIs in Patients With Rare EGFR-mutated NSCLC

NCT01775943 | Unknown

• 1 other identifier: ISSIRES0070
• Study Type: observational
• Target: 90
• Locations: 1 country
• Sites: 1

Brief Summary

Lung cancer is the leading cause of cancer-related death worldwide and is well known to remain a major health problem. Non-small-cell lung cancer (NSCLC) constitutes more than 80% of all the cases of lung cancer. Today, NSCLC can be defined by various molecular criteria. Especially, somatic mutations within the epidermal growth factor receptor (EGFR) gene itself were discovered in a subset of NSCLC patients. Two activating EGFR mutations are in-frame deletion in exon 19 and the substitutions for L858R in exon 21, which account for 85% of all clinically important mutations related to EGFR TKI sensitivity. Besides two activating EGFR mutations, other EGFR mutations in NSCLC have been discovered. G719 and L861 are reported to have intermediate sensitivity to EGFR TKI. And in-frame insertions within exon 20 and T790, which are known to be resistant to EGFR TKIs. However, there are still other EGFR mutations such as E709 and S768 as well as doublet EGFR mutations are also observed. These rare mutations have not been fully described and data on their correlation with response to EGFR-TKIs are still unclear. Research hypothesis Rare EGFR mutations of unknown clinical significance in NSCLC patients, which are distinguish from mutations such as deletion in exon 19, L858 and insertion in exon 20, have some possibility of EGFR TKI sensitivity. Rationale for conducting this study It has an opportunity to be shown the efficacy of EGFR TKIs in patients with rare EGFR mutation in large number of patients in Korea (Asia) during the short period.

Conditions

Lung Neoplasms

Keywords

Epidermal growth factor receptor; Mutation; Lung cancer; Drug sensitivity

Outcome Measures

Primary Outcomes (1)

• the efficacy of EGFR TKIs as defined by objective response rate

  up to 1 year

Secondary Outcomes (1)

• the incidence of patients with rare EGFR mutated NSCLC

  up to 1 year

Other Outcomes (2)

• the clinical characteristics of patients with rare EGFR mutated NSCLC

  up to 1 year

• the efficacy of EGFR TKIs as defined by disease control rate, progression-free survival and overall survival in the patients with rare EGFR mutated NSCLC

  up to 1 year

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

comprehensive cancer hospital

You may qualify if:

• Histological confirmed non-small cell lung cancer (NSCLC), Stage IIIB or stage IV, between January 1, 2008 to December 31, 2011
• Confirmed EGFR rare mutations (EGFR mutation except both exon 19 deletion and exon 21 L858R) using direct DNA sequencing
• Experiences of treatment with EGFR TKIs.
• at least one measurable and/or evaluable lesion according to RECIST criteria (version 1.1)

Sponsors & Collaborators

• Ulsan University Hospital: lead
• AstraZeneca: collaborator

Study Sites (1)

Ulsan University Hospital

Ulsan, 682-060, South Korea

Location

MeSH Terms

Conditions

Lung Neoplasms

Condition Hierarchy (Ancestors)

Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Young Joo Min, M.D.

  Ulsan University Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: January 18, 2013
• First Posted: January 25, 2013
• Study Start: March 1, 2013
• Primary Completion: December 1, 2013
• Study Completion: February 1, 2014
• Last Updated: December 12, 2013

Record last verified: 2013-12

Locations

KR (1)